ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-17 09:00:00,2025-10-17T09:00:00-04:00,2025-10-17,AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin,"Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORTH CHICAGO, Ill.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-gilgamesh-pharmaceuticals-bretisilocin-302587587.html,https://images.financialmodelingprep.com/news/abbvie-completes-acquisition-of-gilgamesh-pharmaceuticals-bretisilocin-20251017.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-17 16:34:32,2025-10-17T16:34:32-04:00,2025-10-17,"AbbVie: ""Strong Buy"" On Rinvoq Expansions And Immunology Pipeline Addition","AbbVie earns a Strong Buy rating in my book, driven by Rinvoq's label expansions and robust immunology pipeline growth. ABBV achieved FDA approval for Rinvoq in giant cell arteritis and reported strong phase 3 results for severe alopecia areata, supporting long-term revenue growth. The acquisition of Capstan Therapeutics brings CPTX2309, a first-in-class tLNP CAR-T candidate, potentially transforming B-cell autoimmune disorder treatment landscape.",seekingalpha.com,https://seekingalpha.com/article/4830869-abbvie-strong-buy-on-rinvoq-expansions-and-immunology-pipeline-addition,https://images.financialmodelingprep.com/news/abbvie-strong-buy-on-rinvoq-expansions-and-immunology-pipeline-addition-20251017.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-20 08:00:00,2025-10-20T08:00:00-04:00,2025-10-20,RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor,Upadacitinib demonstrated superiority versus adalimumab for  primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) and ranked secondary endpoint of remission (DAS28-CRP,prnewswire.com,https://www.prnewswire.com/news-releases/rinvoq-upadacitinib-demonstrated-superiority-versus-humira-adalimumab-for-primary-endpoint-in-a-head-to-head-study-in-rheumatoid-arthritis-patients-who-have-failed-first-tnf-inhibitor-302588110.html,https://images.financialmodelingprep.com/news/rinvoq-upadacitinib-demonstrated-superiority-versus-humira-adalimumab-for-primary-20251020.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-20 08:12:53,2025-10-20T08:12:53-04:00,2025-10-20,AbbVie's Rinvoq shows superiority over Humira in head-to-head study,"AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira, meeting the main goal of a head-to-head trial.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-rinvoq-shows-superiority-over-humira-head-to-head-study-2025-10-20/,https://images.financialmodelingprep.com/news/abbvies-rinvoq-shows-superiority-over-humira-in-headtohead-study-20251020.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-20 11:11:14,2025-10-20T11:11:14-04:00,2025-10-20,Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings,"ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.",zacks.com,https://www.zacks.com/stock/news/2772367/here-s-what-to-expect-from-abbvie-s-oncology-segment-in-q3-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2772367,https://images.financialmodelingprep.com/news/heres-what-to-expect-from-abbvies-oncology-segment-in-q3-20251020.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-21 08:00:00,2025-10-21T08:00:00-04:00,2025-10-21,The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients,"Each winner will be awarded a $20,000 grant to fuel their businesses. Since the program's inception, BOTOX® Cosmetic has awarded more than $1 million in grants to The Confidence Project entrepreneurs.",prnewswire.com,https://www.prnewswire.com/news-releases/the-confidence-project-by-botox-cosmetic-onabotulinumtoxina-unveils-this-years-grant-recipients-302589714.html,https://images.financialmodelingprep.com/news/the-confidence-project-by-botox-cosmetic-onabotulinumtoxina-unveils-this-20251021.jpeg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-21 14:27:27,2025-10-21T14:27:27-04:00,2025-10-21,"Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks",The Investment Committee give you their top stocks to watch for the second half.,youtube.com,https://www.youtube.com/watch?v=P4SFPbDCTN8,https://images.financialmodelingprep.com/news/final-trades-abbvie-qualcomm-aptiv-and-palo-alto-networks-20251021.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-21 21:01:12,2025-10-21T21:01:12-04:00,2025-10-21,This 3 Stocks Portfolio Provides Monthly Income,Who doesn't like payday? Investors can structure a portfolio that provides monthly income with this combination of three stocks.,zacks.com,https://www.zacks.com/stock/news/2773645/this-3-stocks-portfolio-provides-monthly-income?cid=CS-STOCKNEWSAPI-FT-stocks_in_the_news-2773645,https://images.financialmodelingprep.com/news/this-3-stocks-portfolio-provides-monthly-income-20251021.webp
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-22 10:00:20,2025-10-22T10:00:20-04:00,2025-10-22,Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock,"Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",zacks.com,https://www.zacks.com/stock/news/2773877/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2773877,https://images.financialmodelingprep.com/news/here-is-what-to-know-beyond-why-abbvie-inc-20251022.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-22 11:30:39,2025-10-22T11:30:39-04:00,2025-10-22,AbbVie Up More Than 30% in 6 Months: How to Play the Stock,AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.,zacks.com,https://www.zacks.com/stock/news/2774259/abbvie-up-more-than-30-in-6-months-how-to-play-the-stock?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2774259,https://images.financialmodelingprep.com/news/abbvie-up-more-than-30-in-6-months-how-20251022.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-22 18:45:50,2025-10-22T18:45:50-04:00,2025-10-22,AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know,"AbbVie (ABBV) concluded the recent trading session at $228.68, signifying a -1.17% move from its prior day's close.",zacks.com,https://www.zacks.com/stock/news/2774600/abbvie-abbv-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2774600,https://images.financialmodelingprep.com/news/abbvie-abbv-sees-a-more-significant-dip-than-broader-20251022.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-22 19:00:00,2025-10-22T19:00:00-04:00,2025-10-22,AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector,Explore the exciting world of AbbVie (ABBV 1.17%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!,fool.com,https://www.fool.com/investing/2025/10/22/abbvie-navigating-challenges-and-seizing-opportuni/,https://images.financialmodelingprep.com/news/abbvie-navigating-challenges-and-seizing-opportunities-in-the-pharma-20251022.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-23 13:07:54,2025-10-23T13:07:54-04:00,2025-10-23,AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth,"Added 304,281 shares in AbbVie; estimated transaction value of $61.96 million Trade value was 0.23% of the fund's reportable U.S. equity assets under management Post-trade stake: 2,324,286 shares valued at $538.17 million as of September 30, 2025 The position now accounts for 2.01% of 13F assets, placing it outside the fund's top five holdings",fool.com,https://www.fool.com/coverage/filings/2025/10/23/los-angeles-capital-loads-up-abbv-with-304k-shares/,https://images.financialmodelingprep.com/news/abbvie-draws-growing-institutional-confidence-as-investors-seek-steady-20251023.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-24 10:31:20,2025-10-24T10:31:20-04:00,2025-10-24,Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?,"The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.",zacks.com,https://www.zacks.com/stock/news/2776296/wall-street-analysts-think-abbvie-abbv-is-a-good-investment-is-it?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|average_broker_rating-2776296,https://images.financialmodelingprep.com/news/wall-street-analysts-think-abbvie-abbv-is-a-good-20251024.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-24 11:01:21,2025-10-24T11:01:21-04:00,2025-10-24,Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/2776444/analysts-estimate-abbvie-abbv-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2776444,https://images.financialmodelingprep.com/news/analysts-estimate-abbvie-abbv-to-report-a-decline-in-20251024.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-26 02:40:50,2025-10-26T02:40:50-04:00,2025-10-26,Pharmaceutical Stocks To Watch Now – October 24th,"Eli Lilly and Company, Wellgistics Health, Pfizer, AbbVie, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies engaged in the research, development, manufacturing, and sale of prescription drugs, biologics, and vaccines. For investors, these stocks are typically driven by factors like",defenseworld.net,https://www.defenseworld.net/2025/10/26/pharmaceutical-stocks-to-watch-now-october-24th.html,https://images.financialmodelingprep.com/news/pharmaceutical-stocks-to-watch-now-october-24th-20251026.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-26 07:01:35,2025-10-26T07:01:35-04:00,2025-10-26,Wall Street Week Ahead,Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.,seekingalpha.com,https://seekingalpha.com/article/4833469-wall-street-week-ahead,https://images.financialmodelingprep.com/news/wall-street-week-ahead-20251026.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-26 11:21:00,2025-10-26T11:21:00-04:00,2025-10-26,Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade,"AbbVie put a major patent cliff behind it, and won't face another one anytime soon. Apple is building up its services business while looking for ways to get around the threat of tariffs.",fool.com,https://www.fool.com/investing/2025/10/26/prediction-these-dividend-stocks-could-outperform/,https://images.financialmodelingprep.com/news/prediction-these-dividend-stocks-could-outperform-growth-stocks-in-20251026.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-27 12:06:06,2025-10-27T12:06:06-04:00,2025-10-27,What's in Store for These 5 Pharma Bigwigs This Earnings Season?,"As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",zacks.com,https://www.zacks.com/stock/news/2777998/what-s-in-store-for-these-5-pharma-bigwigs-this-earnings-season?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview_esp-2777998,https://images.financialmodelingprep.com/news/whats-in-store-for-these-5-pharma-bigwigs-this-earnings-20251027.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-28 06:26:00,2025-10-28T06:26:00-04:00,2025-10-28,"Billionaire Israel ""Izzy"" Englander Has Loaded Up on This Dividend King. Should You?",Englander more than quintupled his hedge fund's position in AbbVie in Q2. AbbVie offers an impressive dividend record and a solid dividend yield.,fool.com,https://www.fool.com/investing/2025/10/28/billionaire-israel-izzy-englander-has-loaded-up-on/,https://images.financialmodelingprep.com/news/billionaire-israel-izzy-englander-has-loaded-up-on-this-20251028.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-28 09:50:41,2025-10-28T09:50:41-04:00,2025-10-28,Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?,"ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.",zacks.com,https://www.zacks.com/stock/news/2778719/should-you-buy-abbvie-stock-ahead-of-q3-earnings-report?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2778719,https://images.financialmodelingprep.com/news/should-you-buy-abbvie-stock-ahead-of-q3-earnings-20251028.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-28 10:40:55,2025-10-28T10:40:55-04:00,2025-10-28,"Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings","Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.",cnbc.com,https://www.cnbc.com/2025/10/28/healthy-returns-eli-lilly-merck-gilead-and-abbvie-earnings-preview.html,https://images.financialmodelingprep.com/news/healthy-returns-what-to-expect-from-eli-lilly-merck-20251028.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-28 11:28:40,2025-10-28T11:28:40-04:00,2025-10-28,AbbVie: Deep Discount Before Earnings,"AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is investing aggressively in R&D for future growth. The DDM model suggests ABBV is significantly undervalued, with a fair value estimate indicating 27% upside potential over the next year.",seekingalpha.com,https://seekingalpha.com/article/4834058-abbvie-deep-discount-before-earnings,https://images.financialmodelingprep.com/news/abbvie-deep-discount-before-earnings-20251028.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-29 08:11:00,2025-10-29T08:11:00-04:00,2025-10-29,AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo,"In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial Vitiligo Area Scoring Index (F-VASI 75) from baseline at week 481 Both studies met key ranked secondary endpoints1 NORTH CHICAGO, Ill. , Oct. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily  in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of vitiligo (occurring in over 90% of patients), is characterized by symmetrical and bilateral white patches on both sides of the body.2-4 ""Vitiligo is more than a skin condition – it's a chronic autoimmune disease that can deeply affect a person's confidence, identity and daily life,"" said Kori Wallace, M.D.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-announces-positive-topline-results-from-phase-3-pivotal-studies-evaluating-upadacitinib-rinvoq-in-adults-and-adolescents-with-vitiligo-302597634.html,https://images.financialmodelingprep.com/news/abbvie-announces-positive-topline-results-from-phase-3-pivotal-20251029.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-29 17:00:00,2025-10-29T17:00:00-04:00,2025-10-29,The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year,"Allergan Aesthetics gives patients exciting BOTOX® Cosmetic offers only in the Allē app Buy one $50 gift card, get one free, plus, register, book a consultation, and get treated for a chance to win $25,000* † IRVINE, Calif. , Oct. 29, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the seventh annual BOTOX® Cosmetic Day will take place on Wednesday, November 19, 2025.",prnewswire.com,https://www.prnewswire.com/news-releases/the-one--only-botox-cosmetic-onabotulinumtoxina-day-returns-november-19-with-the-biggest-celebration-of-the-year-302598960.html,https://images.financialmodelingprep.com/news/the-one-only-botox-cosmetic-onabotulinumtoxina-day-returns-november-19-20251029.jpeg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 07:49:00,2025-10-31T07:49:00-04:00,2025-10-31,AbbVie Reports Third-Quarter 2025 Financial Results,"Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense   Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis   Third -Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues Were $993 Million    Third -Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.841 Billion, an Increase of 20.2 Percent on a Reported Basis, or 19.6 Percent on an Operational Basis; Global Vraylar Net Revenues Were $934 Million; Global Botox Therapeutic Net Revenues Were $985 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $642 Million   Third -Quarter Global Net Revenues from the Oncology Portfolio Were $1.682 Billion, a Decrease of 0.3 Percent on a Reported Basis, or 1.3 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $706 Million; Global Venclexta Net Revenues Were $726 Million; Global Elahere Net Revenues Were $170 Million   Third -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.193 Billion, a Decrease of 3.7 Percent on a Reported Basis, or 4.2 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $637 Million; Global Juvederm Net Revenues Were $253 Million   Raises 2025 Adjusted Diluted EPS Guidance Range from $10.38 - $10.58 to $10.61 - $10.65, which Includes an Unfavorable Impact of $2.05 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2025   Announces 2026 Dividend Increase of 5.5 Percent, Beginning with Dividend Payable in February 2026 NORTH CHICAGO, Ill. , Oct. 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2025.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2025-financial-results-302600511.html,https://images.financialmodelingprep.com/news/abbvie-reports-thirdquarter-2025-financial-results-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 07:54:43,2025-10-31T07:54:43-04:00,2025-10-31,AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs,"AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped boost third-quarter results above Wall Street estimates.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-annual-profit-forecast-resilient-demand-newer-immunology-drugs-2025-10-31/,https://images.financialmodelingprep.com/news/abbvie-lifts-annual-profit-forecast-on-resilient-demand-for-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 08:20:00,2025-10-31T08:20:00-04:00,2025-10-31,AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.,Revenue attributed to AbbVie's oncology and aesthetics portfolio declined in the quarter.,barrons.com,https://www.barrons.com/articles/abbvie-earnings-stock-price-15008c13,https://images.financialmodelingprep.com/news/abbvie-beats-thirdquarter-estimates-theres-more-to-the-drugmakers-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 08:42:00,2025-10-31T08:42:00-04:00,2025-10-31,AbbVie Lifts Profit Outlook as Sales Rise,"AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.",wsj.com,https://www.wsj.com/business/earnings/abbvie-lifts-profit-outlook-as-sales-rise-2db042c4,https://images.financialmodelingprep.com/news/abbvie-lifts-profit-outlook-as-sales-rise-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 09:02:38,2025-10-31T09:02:38-04:00,2025-10-31,5 Dividend ETFs That Could Pay You for Life,"Whether you're just beginning to invest or sailing into retirement, you can benefit from a lifetime stream of passive income.",247wallst.com,https://247wallst.com/investing/2025/10/31/5-dividend-etfs-that-could-pay-you-for-life/,https://images.financialmodelingprep.com/news/5-dividend-etfs-that-could-pay-you-for-life-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 10:00:59,2025-10-31T10:00:59-04:00,2025-10-31,AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates,"AbbVie (ABBV) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $3 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2782486/abbvie-abbv-q3-earnings-and-revenues-surpass-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2782486,https://images.financialmodelingprep.com/news/abbvie-abbv-q3-earnings-and-revenues-surpass-estimates-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 10:39:51,2025-10-31T10:39:51-04:00,2025-10-31,AbbVie: Why Q3 Confirms Its Immunology Dominance,"AbbVie Inc., 2 hours ago, published monstrous results for Q3, once again strengthening my confidence that it is a ""powerhouse"" in the autoimmune disease drugs market. Net revenues from AbbVie's immunology portfolio totaled $7.89 billion this quarter, compared to $7.05 billion in Q3 2024. Sales of Elahere, an ADC used to treat ovarian cancer, reached $170 million in Q3 2025, up 22.3% year-on-year and 6.9% quarter-on-quarter.",seekingalpha.com,https://seekingalpha.com/article/4836301-abbvie-why-q3-confirms-its-immunology-dominance,https://images.financialmodelingprep.com/news/abbvie-why-q3-confirms-its-immunology-dominance-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 11:47:20,2025-10-31T11:47:20-04:00,2025-10-31,"AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend","AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.",benzinga.com,https://www.benzinga.com/markets/earnings/25/10/48564942/abbvie-raises-2025-outlook-helped-by-strong-immunology-growth-boost-dividend,https://images.financialmodelingprep.com/news/abbvie-raises-2025-outlook-helped-by-strong-immunology-growth-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 12:20:41,2025-10-31T12:20:41-04:00,2025-10-31,AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates,"While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2782812/abbvie-abbv-q3-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2782812,https://images.financialmodelingprep.com/news/abbvie-abbv-q3-earnings-how-key-metrics-compare-to-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 12:20:50,2025-10-31T12:20:50-04:00,2025-10-31,Demographic Megatrend: Stocks Poised to Benefit From Global Aging,"Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.",zacks.com,https://www.zacks.com/stock/news/2782782/demographic-megatrend-stocks-poised-to-benefit-from-global-aging?cid=CS-STOCKNEWSAPI-FT-seniors_&_aging-2782782,https://images.financialmodelingprep.com/news/demographic-megatrend-stocks-poised-to-benefit-from-global-aging-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 15:21:14,2025-10-31T15:21:14-04:00,2025-10-31,"AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised","ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.",zacks.com,https://www.zacks.com/stock/news/2782920/abbvie-q3-earnings-sales-beat-2025-eps-outlook-raised?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2782920,https://images.financialmodelingprep.com/news/abbvie-q3-earnings-sales-beat-2025-eps-outlook-raised-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-10-31 15:56:23,2025-10-31T15:56:23-04:00,2025-10-31,AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript,"AbbVie Inc. ( ABBV ) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDT Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott Reents - Executive VP & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division David Amsellem - Piper Sandler & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Steve Scala - TD Cowen, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Luisa Hector - Joh.",seekingalpha.com,https://seekingalpha.com/article/4836381-abbvie-inc-abbv-q3-2025-earnings-call-transcript,https://images.financialmodelingprep.com/news/abbvie-inc-abbv-q3-2025-earnings-call-transcript-20251031.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-01 06:15:00,2025-11-01T06:15:00-04:00,2025-11-01,Why AbbVie Stock Flopped on Friday,"Despite the pharmaceutical giant's beat-and-raise third quarter, investors were expecting better. Profitability guidance, even though it was raised, came in under analyst estimates.",fool.com,https://www.fool.com/investing/2025/11/01/why-abbvie-stock-flopped-on-friday/,https://images.financialmodelingprep.com/news/why-abbvie-stock-flopped-on-friday-20251101.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-01 10:25:22,2025-11-01T10:25:22-04:00,2025-11-01,Best Dividend Aristocrats For November 2025,"The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW, and IBM have delivered strong double-digit returns this year. Dividend growth for the Aristocrats in 2025 averages 5.27%, with most constituents raising payouts, though growth may not exceed 2024's rate.",seekingalpha.com,https://seekingalpha.com/article/4836679-best-dividend-aristocrats-for-november-2025,https://images.financialmodelingprep.com/news/best-dividend-aristocrats-for-november-2025-20251101.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-01 12:36:08,2025-11-01T12:36:08-04:00,2025-11-01,ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat,AbbVie Inc. NYSE: ABBV delivered a strong third-quarter earnings report with a beat on the top and bottom lines and an increase in its forward guidance. The results clear the way for ABBV stock to make $250 the new floor for the stock.,marketbeat.com,https://www.marketbeat.com/originals/abbv-stock-250-may-be-the-new-floor-after-beat-and-raise-quarter/,https://images.financialmodelingprep.com/news/abbv-stock-250-may-be-the-new-floor-after-20251101.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-01 23:15:00,2025-11-01T23:15:00-04:00,2025-11-01,"ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November","This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. The pattern of modest dividend increases continues, with only three of 19 companies announcing double-digit percentage boosts in October. November brings a larger chance of 10%+ increases from several companies, including industrials Roper Technologies and Snap-on, and healthcare companies Becton, Dickinson and Cencora.",seekingalpha.com,https://seekingalpha.com/article/4836708-adp-snap-on-lead-14-companies-to-announce-annual-increases-first-half-november,https://images.financialmodelingprep.com/news/adp-snapon-lead-14-companies-to-announce-annual-increases-in-20251101.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-02 09:15:00,2025-11-02T09:15:00-05:00,2025-11-02,2 Magnificent Dividend Stocks to Buy and Hold Forever,"Investing in strong dividend stocks is a great way to earn better-than-average long-term returns. AbbVie has a reliable, non-cyclical business and a long and impressive track record of dividend growth.",fool.com,https://www.fool.com/investing/2025/11/02/2-magnificent-dividend-stocks-to-buy-hold-forever/,https://images.financialmodelingprep.com/news/2-magnificent-dividend-stocks-to-buy-and-hold-forever-20251102.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-03 07:30:00,2025-11-03T07:30:00-05:00,2025-11-03,My Favorite Dividend King to Buy in November,AbbVie has increased its dividend for 53 consecutive years and more than quadrupled its dividend since 2013. The drugmaker has a clear growth runway thanks to rising stars in its lineup and a promising pipeline.,fool.com,https://www.fool.com/investing/2025/11/03/my-favorite-dividend-king-to-buy-in-november/,https://images.financialmodelingprep.com/news/my-favorite-dividend-king-to-buy-in-november-20251103.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-04 03:05:01,2025-11-04T03:05:01-05:00,2025-11-04,Top Pharmaceutical Stocks To Follow Now – November 2nd,"Eli Lilly and Company, Pfizer, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and commercialize prescription drugs, vaccines, and related therapies. For investors, they offer exposure to significant R&D and regulatory risk-stock performance is heavily",defenseworld.net,https://www.defenseworld.net/2025/11/04/top-pharmaceutical-stocks-to-follow-now-november-2nd.html,https://images.financialmodelingprep.com/news/top-pharmaceutical-stocks-to-follow-now-november-2nd-20251104.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-04 03:05:04,2025-11-04T03:05:04-05:00,2025-11-04,Best Medical Stocks To Watch Today – November 2nd,"Eli Lilly and Company, Pfizer, UnitedHealth Group, AbbVie, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. ""Medical stocks"" are shares of publicly traded companies that operate in the healthcare sector, including pharmaceutical and biotechnology firms, medical device makers, hospitals, diagnostic labs, and health services providers.",defenseworld.net,https://www.defenseworld.net/2025/11/04/best-medical-stocks-to-watch-today-november-2nd.html,https://images.financialmodelingprep.com/news/best-medical-stocks-to-watch-today-november-2nd-20251104.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-04 05:15:00,2025-11-04T05:15:00-05:00,2025-11-04,2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon,Long-term investors shouldn't overlook this top pharma stock and top medical device maker. AbbVie is seeing impressive growth from both its immunology portfolio and neuroscience products.,fool.com,https://www.fool.com/investing/2025/11/04/2-healthcare-stocks-for-individual-investors-with/,https://images.financialmodelingprep.com/news/2-healthcare-stocks-for-individual-investors-with-a-10year-20251104.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-04 08:11:43,2025-11-04T08:11:43-05:00,2025-11-04,"Here Are Tuesday's Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More","The S&P 500 and NASDAQ futures are trading down over 1% on Tuesday, following Palantir's 6.9% decline despite beating earnings expectations and giving strong forward guidance.",247wallst.com,https://247wallst.com/investing/2025/11/04/here-are-tuesdays-top-wall-street-analyst-research-calls-apple-abbvie-broadcom-cyberark-palantir-technologies-and-more/,https://images.financialmodelingprep.com/news/here-are-tuesdays-top-wall-street-analyst-research-calls-20251104.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-05 02:42:53,2025-11-05T02:42:53-05:00,2025-11-05,AbbVie (NYSE:ABBV) Stock Price Up 1.9% After Analyst Upgrade,AbbVie Inc. (NYSE: ABBV - Get Free Report)'s stock price was up 1.9% during mid-day trading on Tuesday after JPMorgan Chase and Co. raised their price target on the stock from $250.00 to $260.00. JPMorgan Chase and Co. currently has an overweight rating on the stock. AbbVie traded as high as $217.08 and last traded at,defenseworld.net,https://www.defenseworld.net/2025/11/05/abbvie-nyseabbv-stock-price-up-1-9-after-analyst-upgrade.html,https://images.financialmodelingprep.com/news/abbvie-nyseabbv-stock-price-up-19-after-analyst-upgrade-20251105.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-05 10:01:09,2025-11-05T10:01:09-05:00,2025-11-05,Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know,"Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",zacks.com,https://www.zacks.com/stock/news/2785517/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2785517,https://images.financialmodelingprep.com/news/investors-heavily-search-abbvie-inc-abbv-here-is-what-20251105.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-08 06:38:43,2025-11-08T06:38:43-05:00,2025-11-08,Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer,AbbVie's and Pfizer's Q3 earnings and dividend updates prompt a rating upgrade to Hold for ABBV and reiteration of Sell for PFE. PFE's higher yield (almost 7%) and single-digit P/E (FY1 P/E is ~8x only) can be attractive for deep value investors. The high yield and cheap valuation are for good reasons.,seekingalpha.com,https://seekingalpha.com/article/4840843-healthcare-q3-dividend-roundup-i-prefer-abbvie-over-pfizer,https://images.financialmodelingprep.com/news/healthcare-q3-dividend-roundup-i-prefer-abbvie-over-pfizer-20251108.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-09 04:21:00,2025-11-09T04:21:00-05:00,2025-11-09,"Got $5,000? These Are 3 of the Cheapest Growth Stocks to Buy Right Now","The stocks listed here trade at forward price-to-earnings multiples of less than 20. They have underrated growth prospects, which could set them up for better-than-expected gains in the long run.",fool.com,https://www.fool.com/investing/2025/11/09/got-5000-these-are-3-of-the-cheapest-growth-stocks/,https://images.financialmodelingprep.com/news/got-5000-these-are-3-of-the-cheapest-growth-20251109.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-09 11:05:00,2025-11-09T11:05:00-05:00,2025-11-09,What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.,Skyrizi and Rinvoq sales are pushing AbbVie's sales higher. UnitedHealth Group raised its full-year guidance and is rebounding from a disastrous 2025.,fool.com,https://www.fool.com/investing/2025/11/09/what-is-considered-a-good-stock-dividend-3-healthc/,https://images.financialmodelingprep.com/news/what-is-considered-a-good-stock-dividend-3-healthcare-stocks-20251109.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-11 08:49:00,2025-11-11T08:49:00-05:00,2025-11-11,5 Top Stocks to Buy in November,"As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all this into consideration and dive into five top stocks I believe could be great additions to your portfolio moving forward.",fool.com,https://www.fool.com/investing/2025/11/11/5-top-stocks-to-buy-in-november/,https://images.financialmodelingprep.com/news/5-top-stocks-to-buy-in-november-20251111.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-11 10:50:08,2025-11-11T10:50:08-05:00,2025-11-11,Three Healthcare Buys That Wall Street Loves,New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.,fool.com,https://www.fool.com/investing/2025/11/11/three-healthcare-buys-that-wall-street-loves/,https://images.financialmodelingprep.com/news/three-healthcare-buys-that-wall-street-loves-20251111.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-11 22:40:33,2025-11-11T22:40:33-05:00,2025-11-11,AbbVie Has Many Bullish Attributes (Technical Analysis),"AbbVie presents a bullish outlook supported by positive earnings, a strong dividend, and robust technical indicators. ABBV beat Q3 earnings and revenue expectations, raised full-year EPS guidance, and boasts a promising drug pipeline with strong Skyrizi and Rinvoq sales. Technically, ABBV trades above its 30-week EMA, shows bullish momentum, increasing institutional volume, and has outperformed the S&P 500 this year.",seekingalpha.com,https://seekingalpha.com/article/4842247-abbvie-has-many-bullish-attributes-technical-analysis,https://images.financialmodelingprep.com/news/abbvie-has-many-bullish-attributes-technical-analysis-20251111.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-12 08:30:00,2025-11-12T08:30:00-05:00,2025-11-12,Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence,"- A total of 17 abstracts, including three accepted for presentation in the Cosmetic ""Top Ten"" Session, underscore Allergan Aesthetics' global industry leadership across multiple aesthetic categories - Oral abstract presentations include Phase 3 clinical study results for first-in-class botulinum neurotoxin serotype E (trenibotulinumtoxinE) and results from a Phase 4 study evaluating natural outcomes and patient satisfaction in a diverse population following use of 64 units of BOTOX® Cosmetic (onabotulinumtoxinA) for treatment of upper facial lines - Expert panel discussion explores new Hyaluronic Acid Injectable Fillers Report, along with current use, facts, and real-world satisfaction data IRVINE, Calif. , Nov. 12, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society of Dermatologic Surgery (ASDS) Annual Meeting, November 13-16, 2025, in Chicago, Illinois.",prnewswire.com,https://www.prnewswire.com/news-releases/allergan-aesthetics-unveils-new-data-at-2025-american-society-for-dermatologic-surgery-annual-meeting-showcasing-transformative-innovation-and-portfolio-excellence-302611934.html,https://images.financialmodelingprep.com/news/allergan-aesthetics-unveils-new-data-at-2025-american-society-20251112.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-12 08:30:00,2025-11-12T08:30:00-05:00,2025-11-12,"Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders","PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to address challenging disease areas with high unmet need.",globenewswire.com,https://www.globenewswire.com/news-release/2025/11/12/3186250/0/en/Chiesi-Group-Enters-into-an-Exclusive-License-Agreement-with-Aliada-Therapeutics-a-Wholly-Owned-Subsidiary-of-AbbVie-to-Advance-Blood-Brain-Barrier-Crossing-Platform-Technology-in-.html,https://images.financialmodelingprep.com/news/chiesi-group-enters-into-an-exclusive-license-agreement-with-20251112.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-12 12:56:11,2025-11-12T12:56:11-05:00,2025-11-12,How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?,ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.,zacks.com,https://www.zacks.com/stock/news/2790121/how-much-did-skyrizi-and-rinvoq-drive-abbvie-s-q3-performance?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2790121,https://images.financialmodelingprep.com/news/how-much-did-skyrizi-and-rinvoq-drive-abbvies-q3-performance-20251112.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-12 15:06:26,2025-11-12T15:06:26-05:00,2025-11-12,AbbVie Shares Rise To Intraday High After Key Trading Signal,"AbbVie Inc (NYSE:ABBV) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.At 10:04 AM EST on November 12, ABBV triggered a Power Inflow signal at a price of $228.47. In the hour leading up to the Power Inflow signal, ABBV's stock price had some slight pullback following the initial price rise that occurred earlier in the day.",benzinga.com,https://www.benzinga.com/Opinion/25/11/48816772/abbvie-shares-rise-to-intraday-high-after-key-trading-signal,https://images.financialmodelingprep.com/news/abbvie-shares-rise-to-intraday-high-after-key-trading-20251112.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-13 08:10:11,2025-11-13T08:10:11-05:00,2025-11-13,"Here Are Thursday's Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More","The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction.",247wallst.com,https://247wallst.com/investing/2025/11/13/here-are-thursdays-top-wall-street-analyst-research-calls-abbvie-applovin-autozone-booking-holdings-coreweave-doordash-and-more/,https://images.financialmodelingprep.com/news/here-are-thursdays-top-wall-street-analyst-research-calls-20251113.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-13 08:30:00,2025-11-13T08:30:00-05:00,2025-11-13,AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™,"As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace. 2025 honorees represent a diverse group of achievers—from teachers and authors to small business owners and aspiring yoga and meditation instructors—each redefining success while living with migraine.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-announces-20-recipients-of-migraine-career-catalyst-award-302613759.html,https://images.financialmodelingprep.com/news/abbvie-announces-20-recipients-of-migraine-career-catalyst-award-20251113.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-13 16:02:00,2025-11-13T16:02:00-05:00,2025-11-13,Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact,"Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for",gurufocus.com,https://www.gurufocus.com/news/3207779/robert-bruces-strategic-moves-att-inc-sees-a-141-portfolio-impact,https://images.financialmodelingprep.com/news/robert-bruces-strategic-moves-att-inc-sees-a-141-portfolio-20251113.png
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-14 04:12:52,2025-11-14T04:12:52-05:00,2025-11-14,Arvest Bank Trust Division Sells 323 Shares of AbbVie Inc. $ABBV,"Arvest Bank Trust Division decreased its stake in shares of AbbVie Inc. (NYSE: ABBV) by 0.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,971 shares of the company's stock after selling 323 shares during the quarter. AbbVie comprises about",defenseworld.net,https://www.defenseworld.net/2025/11/14/arvest-bank-trust-division-sells-323-shares-of-abbvie-inc-abbv.html,https://images.financialmodelingprep.com/news/arvest-bank-trust-division-sells-323-shares-of-abbvie-inc-20251114.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-14 15:19:12,2025-11-14T15:19:12-05:00,2025-11-14,Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman,"Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.",youtube.com,https://www.youtube.com/watch?v=X24CQW_cpss,https://images.financialmodelingprep.com/news/biopharma-companies-have-confidence-in-their-ability-to-do-20251114.jpg
ABBV,2025-10-31,2025-10-17,2025-11-14,ABBV,,2025-11-14 16:31:33,2025-11-14T16:31:33-05:00,2025-11-14,AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript,"AbbVie Inc. ( ABBV ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michael Paas Conference Call Participants Elena Meng Michelle Kehily Stephen Morse Magdalena Sobieszczyk Presentation Operator Okay, everyone, if we can wrap up our conversations so that we can get started and come to the main room. So our final panel today is about vaccines.",seekingalpha.com,https://seekingalpha.com/article/4843997-abbvie-inc-abbv-presents-at-7th-annual-healthcare-symposium-transcript,https://images.financialmodelingprep.com/news/abbvie-inc-abbv-presents-at-7th-annual-healthcare-symposium-20251114.jpg
